<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621E4323-5F3F-488B-A1ED-D31C5A134CD5"><gtr:id>621E4323-5F3F-488B-A1ED-D31C5A134CD5</gtr:id><gtr:name>Puridify</gtr:name><gtr:address><gtr:line1>Basement Flat
93 Camden Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0HP</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621E4323-5F3F-488B-A1ED-D31C5A134CD5"><gtr:id>621E4323-5F3F-488B-A1ED-D31C5A134CD5</gtr:id><gtr:name>Puridify</gtr:name><gtr:address><gtr:line1>Basement Flat
93 Camden Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0HP</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/782A4DB8-9169-46F8-8C93-1EE564C0EE63"><gtr:id>782A4DB8-9169-46F8-8C93-1EE564C0EE63</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/504F088E-0E6B-4549-97DC-62154A607BCB"><gtr:id>504F088E-0E6B-4549-97DC-62154A607BCB</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Kinghorn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14118"><gtr:id>094F7E52-6C82-4332-AC9D-E5CE0D76E4A2</gtr:id><gtr:title>The MRC Confidence in Concepts at UCL Fund 2014</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14118</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>700000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Gale CiC Collaboration with GSK</gtr:description><gtr:id>2821EEA1-5159-49A3-8B80-03F41F8F64A5</gtr:id><gtr:impact>Project completed disproving published literature data.
The collaboration continues through the appointment of Rick Cousins (GSK) as a visiting professor to UCL.</gtr:impact><gtr:outcomeId>56e1466ca604b4.83764944-1</gtr:outcomeId><gtr:partnerContribution>In vitro compound screening and provision of modulator compounds</gtr:partnerContribution><gtr:piContribution>Project proposal around the development of notch pathway modulators in the treatment of hearing loss. Project team provides theoretical, technical and practical disease biology expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Mookerjee CiC collaboration with Medimmune</gtr:description><gtr:id>F884498C-B7C2-451C-BAE4-946AF4056365</gtr:id><gtr:impact>Agreement with Medimmune to supply protein</gtr:impact><gtr:outcomeId>56e14f99cf6194.68792861-1</gtr:outcomeId><gtr:partnerContribution>Generation and scaled up preparation of a key rat isoform of the LCAT protein needed in the project.</gtr:partnerContribution><gtr:piContribution>Development of research project proposal and plan. Disease and biology expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Holmes CiC collaboration with Evotec</gtr:description><gtr:id>DE023AE6-B879-47FE-8010-720F7BAC54C0</gtr:id><gtr:impact>Collaboration led to the development of a Wellcome Trust SDDI application that had to be withdrawn at the full stage due to illness. The project team is seeking alternative approaches to exploiting the data package generated.
Multi-disciplinary - Chemistry, cheminformatics, biology, structural biology, clinical.</gtr:impact><gtr:outcomeId>56e14b984bdd23.97576939-1</gtr:outcomeId><gtr:partnerContribution>Provided high quality primary screening, medicinal chemistry and xray crystallography</gtr:partnerContribution><gtr:piContribution>Developed project proposal and plan. Provided theoretical and practical disease expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Puridify</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Nathwani CiC collaboration with Puridify</gtr:description><gtr:id>634169CF-0958-4BBF-8743-24C2729DC836</gtr:id><gtr:impact>Too early to be specific</gtr:impact><gtr:outcomeId>56e1519f105d42.96413175-1</gtr:outcomeId><gtr:partnerContribution>Technical expertise in the production and purification of AAV vectors</gtr:partnerContribution><gtr:piContribution>Development of the project proposal and plan. Theoretical, technical and practical biological and disease expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>79967</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LiDo Studentship Award -O'Brien</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F0F69C2D-4536-4E05-93BF-554C24A43A92</gtr:id><gtr:outcomeId>58c68b0037a1e1.24849563</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>273288</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Wellcome Trust Clinical Training Fellopwship - O'brien/George</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>510437A3-0DB1-49DD-A159-8476F4FCBC8B</gtr:id><gtr:outcomeId>56e16614a31f41.51007341</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460940</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - O'Brien</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1B1239DB-9369-44F6-B4B6-03BFEF14E983</gtr:id><gtr:outcomeId>58c68b5e368fe9.10719555</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gamma Healthcare - Day</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Gamma Healthcare</gtr:fundingOrg><gtr:id>90B0141E-5822-4C01-B756-3A95C322750B</gtr:id><gtr:outcomeId>56e166dc553df5.44351768</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>UCLH BRC (SBC) grant - Day</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4496B251-69FE-4C92-A6C0-CC8086B3AA1D</gtr:id><gtr:outcomeId>58c68bf5ae6a46.61224968</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the production of microspheres having radial pores using thermally induced phase separation, especially microspheres for use in tissue engineering.</gtr:description><gtr:grantRef>MC_PC_14118</gtr:grantRef><gtr:id>23634A04-9298-4DFF-A591-F5C210839145</gtr:id><gtr:impact>Too early</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c692eacb4ca1.36139857</gtr:outcomeId><gtr:patentId>WO2008155558 A3</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Microspheres</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a muscle conditioning device comprising one or more implantable bodies and an actuator, where in use, the implantable bodies are magnetically coupled to the actuator and are resiliently positionable to administer mechanical strain to the muscle on operation of the actuator. It also relates to individual elements of the device; to compositions and kits thereof; and to uses of and methods involving the device.</gtr:description><gtr:grantRef>MC_PC_14118</gtr:grantRef><gtr:id>06690E73-288E-4771-872B-BB89021CF8F2</gtr:id><gtr:impact>Too early</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c69247cba203.41049595</gtr:outcomeId><gtr:patentId>WO2014091182 A8</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Muscle conditioning device</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Orchard Therapeutics Ltd</gtr:companyName><gtr:description>Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases

Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders

We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy

Our mission is to translate results from pre-clinical and early clinical research into commercially approved gene therapies for patients around the world</gtr:description><gtr:id>899E5E83-8465-4430-9CC4-F654FC53BDFB</gtr:id><gtr:impact>Currently have one program in clinical development aiming to submit for marketing approval 2018/19</gtr:impact><gtr:outcomeId>58c68dd8e16946.89948844</gtr:outcomeId><gtr:url>http://orchard-tx.com/</gtr:url><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>6CF83E8D-79DA-4327-9136-201B8CAE5744</gtr:id><gtr:title>Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81c32c19ade8dc9e360d1bc9c6d18f32"><gtr:id>81c32c19ade8dc9e360d1bc9c6d18f32</gtr:id><gtr:otherNames>Vink CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5aa6ac7f40d4b8.88246157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71CAFB3A-8FF1-4997-926E-25B5A07F7DFF</gtr:id><gtr:title>Lentiviral vectors can be used for full-length dystrophin gene therapy.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8285b708ad4a42037c271ee593f4e236"><gtr:id>8285b708ad4a42037c271ee593f4e236</gtr:id><gtr:otherNames>Counsell JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa6acf32ae6c7.88336833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5F08B3B-18CE-4CFD-A70A-6572191D735A</gtr:id><gtr:title>The Effect of Hypothermic and Cryogenic Preservation on Engineered Neural Tissue.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part C, Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd72a88ee126ebd09f26883cc427ec40"><gtr:id>dd72a88ee126ebd09f26883cc427ec40</gtr:id><gtr:otherNames>Day AGE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1937-3384</gtr:issn><gtr:outcomeId>5aa6adb01a9422.15608200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B28FFB3-9D0D-407B-83AD-57545880F3F4</gtr:id><gtr:title>Haemophilia B curative FIX production from a low dose UCOE-based lentiviral vector following hepatic pre-natal delivery.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b448d19e2ae7e50e02e0ffb78eb7a06"><gtr:id>7b448d19e2ae7e50e02e0ffb78eb7a06</gtr:id><gtr:otherNames>Kao VY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn><gtr:outcomeId>58c697988c6df3.35636670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>259646D0-B4B2-495A-B58F-7105B710BACD</gtr:id><gtr:title>NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/985daa6c682db24b1c2b0b9d0de8b00b"><gtr:id>985daa6c682db24b1c2b0b9d0de8b00b</gtr:id><gtr:otherNames>Hawkins KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c6984d364ec2.49893395</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14118</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>